Direct renin inhibition: clinical pharmacology (Q37119806)

18 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Direct renin inhibition: clinical pharmacology (English)

1 reference

18 August 2017

1 reference

Michel Azizi

1

1 reference

18 August 2017

27 March 2008

1 reference

Journal of Molecular Medicine

18 August 2017

1 reference

18 August 2017

86

1 reference

18 August 2017

6

1 reference

18 August 2017

647-654

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-008-0329-z

18 August 2017

0 references

cites work

Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Dose-Dependent Effects of the Renin Inhibitor Zankiren HCl After a Single Oral Dose in Mildly Sodium-Depleted Normotensive Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-008-0329-Z

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

21 January 2018

1 reference

12 December 2020

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

1 reference

12 December 2020

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension

1 reference

12 December 2020

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

1 reference

12 December 2020

Renin inhibition: what are the therapeutic opportunities?

1 reference

12 December 2020

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

1 reference

12 December 2020

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

1 reference

12 December 2020

Lectin chromatography of extrarenal renin protein in human plasma and tissues: potential endocrine function via the renin receptor

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans

1 reference

12 December 2020

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

1 reference

12 December 2020

Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans

1 reference

12 December 2020

Conformational changes in prorenin during renin inhibition in vitro and in vivo

1 reference

12 December 2020

Renal vascular responses to renin inhibition with zankiren in men*

1 reference

12 December 2020

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

1 reference

12 December 2020

Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive

1 reference

12 December 2020

Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells

1 reference

12 December 2020

Aliskiren: a review of its use in the management of hypertension

1 reference

12 December 2020

Oral renin inhibitors

1 reference

12 December 2020

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

12 December 2020

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

12 December 2020

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

12 December 2020

Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver

1 reference

12 December 2020

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

12 December 2020

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine

1 reference

12 December 2020

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

12 December 2020

Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications

1 reference

12 December 2020

Dual inhibition of the renin system by aliskiren and valsartan

1 reference

12 December 2020

Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation.

1 reference

12 December 2020

A brief response to Sealey and Laragh

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

12 December 2020

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"

1 reference

12 December 2020

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

12 December 2020

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

12 December 2020

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

12 December 2020

Contribution of bradykinin and nitric oxide to AT2 receptor‐mediated differentiation in PC12 W cells

1 reference

12 December 2020

Renin, prorenin and the putative (pro)renin receptor

1 reference

12 December 2020

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

12 December 2020

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

1 reference

12 December 2020

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals

1 reference

12 December 2020

The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren

1 reference

12 December 2020

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

1 reference

12 December 2020

Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension

1 reference

12 December 2020

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

12 December 2020

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

12 December 2020

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects

1 reference

12 December 2020

Aldosterone in the development and progression of renal injury

1 reference

12 December 2020

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

12 December 2020

Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody

1 reference

12 December 2020

A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension

1 reference

12 December 2020

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

1 reference

12 December 2020

The paradox of the low-renin state in diabetic nephropathy

1 reference

12 December 2020

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects

1 reference

12 December 2020

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

1 reference

12 December 2020

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

12 December 2020

A place in our hearts for the lowly angiotensin 1-7 peptide?

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

1 reference

12 December 2020

Renin inhibition improves pressure natriuresis in essential hypertension.

1 reference

12 December 2020

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

1 reference

12 December 2020

Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus

1 reference

12 December 2020

Interpretation of plasma renin concentration in patients receiving aliskiren therapy

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment

1 reference

12 December 2020

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

12 December 2020

Letter by Fisher and Johns regarding article, "Variable platelet response to aspirin and clopidogrel in atherothrombotic disease".

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1007/S00109-008-0329-Z

Number of visits at goal blood pressure is associated with improved cardiovascular outcomes--a post hoc analysis of the INVEST trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1007/S00109-008-0329-Z

Identifiers

DOI

10.1007/S00109-008-0329-Z

1 reference

18 August 2017

1 reference

PubMed ID

18368379